148 related articles for article (PubMed ID: 8549307)
1. Activity of levofloxacin, ofloxacin, D-ofloxacin and ciprofloxacin against systemic and respiratory tract infections in laboratory animals.
Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Seibert G; Iyer P
Drugs; 1995; 49 Suppl 2():211-4. PubMed ID: 8549307
[No Abstract] [Full Text] [Related]
2. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Iyer P
J Antimicrob Chemother; 1995 Jun; 35(6):805-19. PubMed ID: 7559192
[TBL] [Abstract][Full Text] [Related]
3. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
Langtry HD; Lamb HM
Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
[TBL] [Abstract][Full Text] [Related]
5. The fluoroquinolones after ciprofloxacin and ofloxacin.
Hooper DC
Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519
[No Abstract] [Full Text] [Related]
6. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
[TBL] [Abstract][Full Text] [Related]
7. New fluoroquinolone antibiotics.
Drug Ther Bull; 1999 Jan; 37(1):6-8. PubMed ID: 10562769
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Wise R; Andrews JM
J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
[TBL] [Abstract][Full Text] [Related]
9. [Recent fluoroquinolones. Highly effective weapons for ambulatory therapy].
Stahlmann R; Lode H
MMW Fortschr Med; 1999 Nov; 141(47):35-6. PubMed ID: 10912165
[No Abstract] [Full Text] [Related]
10. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Martin SJ; Jung R; Garvin CG
Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
Obana Y; Nishino T
Drugs Exp Clin Res; 1988; 14(5):327-31. PubMed ID: 3219995
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolones in respiratory infections.
Klein NC
Semin Respir Infect; 1991 Sep; 6(3):131-5. PubMed ID: 1754733
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.
Hayashi K; Kadowaki SE; Takei M; Fukuda H
Antimicrob Agents Chemother; 2006 Feb; 50(2):748-51. PubMed ID: 16436736
[TBL] [Abstract][Full Text] [Related]
15. [Levofloxacin in the treatment of respiratory infections].
Iakovlev SV; Iakovlev VP
Antibiot Khimioter; 2002; 47(8):32-42. PubMed ID: 12515095
[No Abstract] [Full Text] [Related]
16. [Levofloxacin for prevalent infections in primary care medicine].
Redondo Sánchez J
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():29-33. PubMed ID: 10563108
[No Abstract] [Full Text] [Related]
17. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of levofloxacin in low respiratory tract infection].
Zubkov MN
Antibiot Khimioter; 2004; 49(5):31-7. PubMed ID: 15573900
[No Abstract] [Full Text] [Related]
20. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
